Mendeley出力
＜学術雑誌論文＞
国内第3波でのCOVID-19症例集積研究およびCOVID-19肺炎治療中の増悪時におけるバイオマーカー推移とマネジメントの検討（単施設研究）
| 作成者 | |
|---|---|
| 本文言語 | |
| 出版者 | |
| 発行日 | |
| 収録物名 | |
| 巻 | |
| 号 | |
| 開始ページ | |
| 終了ページ | |
| 出版タイプ | |
| アクセス権 | |
| JaLC DOI | |
| 概要 | Background : To date, there has been no silver bullet against Coronavirus disease 2019 (COVID-19). After starting an initial treatment, we sometimes experience an exacerbation of pneumonia due to COVI...D-19. Patients and Methods: To begin with, we retrospectively summarized our series of COVID-19 cases hospitalized during a third wave of COVID-19 in Japan (November, 2020 - March, 2021). Then we extracted exacerbated cases for further analysis and focused on changes in the laboratory data and its management Results : Thirty patients participated in this study. The mean age ± standard deviation was 70.9 ± 15.0. Twenty patients needed oxygen supply at the time of admission. Most of the administered medication was corticosteroid (24 cases). However, during the corticosteroid treatment, five patients experienced the exacerbation of pneumonia due to COVID-19. Among laboratory tests, the elevation of lactate dehydrogenase was detected at an exacerbation (four cases). With the exception of one patient transferred to another hospital, we raised the dose of corticosteroids for three cases. Although one patient died, the others finally improved. Conclusion : Lactate dehydrogenase might be a sensitive marker for cases of an exacerbation of pneumonia due to COVID-19, and the intensification of treatments such as high-doses of corticosteroids could be helpful in some cases.続きを見る |
詳細
| PISSN | |
|---|---|
| NCID | |
| レコードID | |
| 査読有無 | |
| 主題 | |
| タイプ | |
| 登録日 | 2022.01.11 |
| 更新日 | 2023.11.21 |